SAB Biotherapeutics
SABS
SABS
37 hedge funds and large institutions have $92.7M invested in SAB Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Holders
37
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$5.3M | |
| 2 | +$5.26M | |
| 3 | +$4.4M | |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$3.98M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$3.49M |
Top Sellers
| 1 | -$5.09M | |
| 2 | -$983K | |
| 3 | -$498K | |
| 4 |
MSU
Mizuho Securities USA
New York
|
-$203K |
| 5 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$183K |